{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:22:21Z","timestamp":1784809341872,"version":"3.55.0"},"reference-count":72,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mazandaran University of Medical Sciences (MAZUMS)","award":["10282"],"award-info":[{"award-number":["10282"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Previous studies indicated that natural-based chalcones have significant inhibitory effects on the coronavirus enzymes 3CLpro and PLpro as well as modulation of some host-based antiviral targets (HBATs). In this study, a comprehensive computational and structural study was performed to investigate the affinity of our compound library consisting of 757 chalcone-based structures (CHA-1 to CHA-757) for inhibiting the 3CLpro and PLpro enzymes and against twelve selected host-based targets. Our results indicated that CHA-12 (VUF 4819) is the most potent and multi-target inhibitor in our chemical library over all viral and host-based targets. Correspondingly, CHA-384 and its congeners containing ureide moieties were found to be potent and selective 3CLpro inhibitors, and benzotriazole moiety in CHA-37 was found to be a main fragment for inhibiting the 3CLpro and PLpro. Surprisingly, our results indicate that the ureide and sulfonamide moieties are integral fragments for the optimum 3CLpro inhibition while occupying the S1 and S3 subsites, which is fully consistent with recent reports on the site-specific 3CLpro inhibitors. Finding the multi-target inhibitor CHA-12, previously reported as an LTD4 antagonist for the treatment of inflammatory pulmonary diseases, prompted us to suggest it as a concomitant agent for relieving respiratory symptoms and suppressing COVID-19 infection.<\/jats:p>","DOI":"10.3390\/ijms24108789","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:37:51Z","timestamp":1684204671000},"page":"8789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-3743","authenticated-orcid":false,"given":"Mehdi","family":"Valipour","sequence":"first","affiliation":[{"name":"Razi Drug Research Center, Iran University of Medical Sciences, Tehran 1545913487, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-6644","authenticated-orcid":false,"given":"Silvia","family":"Di Giacomo","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology \u201cV. Erspamer\u201d, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-1689","authenticated-orcid":false,"given":"Antonella","family":"Di Sotto","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology \u201cV. Erspamer\u201d, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-6162","authenticated-orcid":false,"given":"Hamid","family":"Irannejad","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari 4847116547, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113157","DOI":"10.1016\/j.ejmech.2021.113157","article-title":"The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2","volume":"213","author":"Ahmad","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","article-title":"The architecture of SARS-CoV-2 transcriptome","volume":"181","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"114426","DOI":"10.1016\/j.ejmech.2022.114426","article-title":"Identification, optimization, and biological evaluation of 3-O-\u03b2-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein","volume":"238","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/acsptsci.0c00216","article-title":"Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen","volume":"4","author":"Kuzikov","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/acsptsci.2c00026","article-title":"Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor","volume":"5","author":"Glaser","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/s41467-020-18709-w","article-title":"Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease","volume":"11","author":"Douangamath","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mengist, H.M., Dilnessa, T., and Jin, T. (2021). Structural basis of potential inhibitors targeting SARS-CoV-2 main protease. Front. Chem., 9.","DOI":"10.3389\/fchem.2021.622898"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2006.03.004","article-title":"Antiviral drug resistance","volume":"71","author":"Richman","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.idc.2010.07.001","article-title":"Antiviral drug resistance: Mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect. Dis. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13073-014-0115-1","article-title":"Virus-host interactomics: New insights and opportunities for antiviral drug discovery","volume":"6","author":"Vonderscher","year":"2014","journal-title":"Genome Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"116356","DOI":"10.1016\/j.bmc.2021.116356","article-title":"Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens","volume":"46","author":"Mahajan","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/acsptsci.2c00003","article-title":"Allosteric Site of ACE-2 as a Drug Target for COVID-19","volume":"5","author":"Dutta","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.apsb.2020.09.003","article-title":"Increased plasma ACE2 concentration does not mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apsb.2020.10.006","article-title":"Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator","volume":"11","author":"Bian","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.apsb.2021.05.007","article-title":"SARS-CoV-2 cell entry and targeted antiviral development","volume":"11","author":"Chen","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eabe0751","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yjmcc.2020.05.007","article-title":"p38 MAPK inhibition: A promising therapeutic approach for COVID-19","volume":"144","author":"Grimes","year":"2020","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.tim.2021.01.014","article-title":"Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics","volume":"29","author":"Felip","year":"2021","journal-title":"Trends Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13238-020-00769-9","article-title":"Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase","volume":"11","author":"Xu","year":"2020","journal-title":"Protein Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.apsb.2021.06.016","article-title":"Recent advances in developing small-molecule inhibitors against SARS-CoV-2","volume":"12","author":"Xiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.apsb.2021.08.027","article-title":"Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors","volume":"12","author":"Gao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104965","DOI":"10.1016\/j.compbiomed.2021.104965","article-title":"Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach","volume":"139","author":"Singh","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"128933","DOI":"10.1016\/j.foodchem.2020.128933","article-title":"An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2","volume":"346","author":"Sharma","year":"2021","journal-title":"Food Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jtcme.2021.05.005","article-title":"In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors","volume":"12","author":"Singh","year":"2022","journal-title":"J. Tradit. Complement. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104631","DOI":"10.1016\/j.compbiomed.2021.104631","article-title":"Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors","volume":"136","author":"Singh","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105572","DOI":"10.1016\/j.compbiomed.2022.105572","article-title":"Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations","volume":"146","author":"Singh","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"173448","DOI":"10.1016\/j.ejphar.2020.173448","article-title":"In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2","volume":"886","author":"Vijayakumar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ddr.21961","article-title":"Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs)","volume":"83","author":"Valipour","year":"2022","journal-title":"Drug Dev. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/acsptsci.2c00045","article-title":"Different Aspects of Emetine\u2019s Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19","volume":"5","author":"Valipour","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/15384101.2021.1982509","article-title":"Therapeutic potential of chelerythrine as a multi-purpose adjuvant for the treatment of COVID-19","volume":"20","author":"Valipour","year":"2021","journal-title":"Cell Cycle"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/15384101.2022.2100575","article-title":"Application of emetine in SARS-CoV-2 treatment: Regulation of p38 MAPK signaling pathway for preventing emetine-induced cardiac complications","volume":"21","author":"Valipour","year":"2022","journal-title":"Cell Cycle"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"114572","DOI":"10.1016\/j.ejmech.2022.114572","article-title":"Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV\/SARS-CoV-2 papain-like protease inhibitors","volume":"240","author":"Valipour","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/17460441.2019.1573812","article-title":"Recent developments in biological aspects of chalcones: The odyssey continues","volume":"14","author":"Rani","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/1061186X.2020.1853759","article-title":"A comprehensive review on the antiviral activities of chalcones","volume":"29","author":"Elkhalifa","year":"2021","journal-title":"J. Drug Target."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/14756366.2014.1003215","article-title":"Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV","volume":"31","author":"Park","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hu, Y., Liu, M., Qin, H., Lin, H., An, X., Shi, Z., Song, L., Yang, X., Fan, H., and Tong, Y. (2021). Artemether, artesunate, arteannuin B, echinatin, licochalcone B and andrographolide effectively inhibit SARS-CoV-2 and related viruses in vitro. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.680127"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/14756366.2016.1265519","article-title":"Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors","volume":"32","author":"Park","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/14756366.2012.753591","article-title":"Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia","volume":"29","author":"Kim","year":"2014","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1111\/cbdd.13604","article-title":"Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors","volume":"94","author":"Jo","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1002\/ptr.7651","article-title":"Recruitment of chalcone\u2019s potential in drug discovery of a nti-SARS-CoV-2 agents","volume":"36","author":"Valipour","year":"2022","journal-title":"Phytother. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/jm960628d","article-title":"Synthesis and Structure\u2212Activity Relationships of Carboxylated Chalcones: A Novel Series of CysLT 1 (LTD4) Receptor Antagonists","volume":"40","author":"Zwaagstra","year":"1997","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Giordo, R., Zinellu, A., Eid, A.H., and Pintus, G. (2021). Therapeutic potential of resveratrol in COVID-19-associated hemostatic disorders. Molecules, 26.","DOI":"10.3390\/molecules26040856"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rossi, G.A., Sacco, O., Capizzi, A., and Mastromarino, P. (2021). Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.670955"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ptr.6887","article-title":"A role for quercetin in coronavirus disease 2019 (COVID-19)","volume":"35","author":"Derosa","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1568026013395001","article-title":"Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery","volume":"1","author":"Yan","year":"2001","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.drudis.2006.05.001","article-title":"Designing better drugs: Predicting cytochrome P450 metabolism","volume":"11","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bengtson, C.D., Montgomery, R.N., Nazir, U., Satterwhite, L., Kim, M.D., Bahr, N.C., Castro, M., Baumlin, N., and Salathe, M. (2021). An open label trial to assess safety of losartan for treating worsening respiratory illness in COVID-19. Front. Med., 8.","DOI":"10.3389\/fmed.2021.630209"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e14124","DOI":"10.1111\/ijcp.14124","article-title":"Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial","volume":"75","author":"Kalami","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100957","DOI":"10.1016\/j.eclinm.2021.100957","article-title":"A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19","volume":"37","author":"Puskarich","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","article-title":"Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia","volume":"10","author":"Geriak","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1017\/ice.2020.80","article-title":"A potential protective role of losartan against coronavirus-induced lung damage","volume":"41","author":"Zeinalian","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Shen, Z., Ratia, K., Cooper, L., Kong, D., Lee, H., Kwon, Y., Li, Y., Alqarni, S., Huang, F., and Dubrovskyi, O. (2021). Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures. bioRxiv.","DOI":"10.1101\/2021.02.13.431008"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1248\/bpb.b12-00623","article-title":"Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus","volume":"35","author":"Park","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1016\/j.bmcl.2005.08.087","article-title":"Sulfonamide chalcone as a new class of \u03b1-glucosidase inhibitors","volume":"15","author":"Seo","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1042\/BST20200505","article-title":"\u03b1-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19","volume":"48","author":"Williams","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/acs.jmedchem.0c00403","article-title":"Mining the PDB for Tractable Cases Where X-ray Crystallography Combined with Fragment Screens Can Be Used to Systematically Design Protein\u2013Protein Inhibitors: Two Test Cases Illustrated by IL1\u03b2-IL1R and p38\u03b1\u2013TAB1 Complexes","volume":"63","author":"Nichols","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1016\/j.bmcl.2008.08.082","article-title":"Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors","volume":"18","author":"Ghosh","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cmdc.202000548","article-title":"Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2","volume":"16","author":"Welker","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1021\/jm058208o","article-title":"Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives","volume":"48","author":"Rodrigues","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm401712t","article-title":"X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases","volume":"57","author":"Barraza","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.chembiol.2005.12.008","article-title":"Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease","volume":"13","author":"Wu","year":"2006","journal-title":"Chem. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1016\/j.bmcl.2013.08.112","article-title":"Discovery of N-(benzo [1, 2, 3] triazol-1-yl)-N-(benzyl) acetamido) phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding","volume":"23","author":"Turlington","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cbdd.13411","article-title":"In vitro and in silico evaluation of P-glycoprotein inhibition through 99mTc-methoxyisobutylisonitrile uptake","volume":"93","author":"Balef","year":"2019","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_71","unstructured":"Goodarzi, A., Valipour, M., and Irannejad, H. (2023). Affinity Prediction of Shikonins towards Sirtuins and the Requisite Structural Motifs for the Selective Inhibition of SIRT2 and SIRT3. Lett. Drug Des. Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS","volume":"17","author":"Valiente","year":"2021","journal-title":"J. Chem. Theory Comput."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:35:37Z","timestamp":1760124937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24108789"],"URL":"https:\/\/doi.org\/10.3390\/ijms24108789","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]}}}